Plus Therapeutics (PSTV) Competitors

$5.83 -0.01 (-0.17%)

Closing price 05/19/2026 04:00 PM Eastern

Extended Trading

$5.73 -0.10 (-1.72%)

As of 05/19/2026 07:59 PM Eastern

PSTV vs. STEX, HYPR, EDAP, APYX, and MBOT

Should you buy Plus Therapeutics stock or one of its competitors? MarketBeat compares Plus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Plus Therapeutics include Biosig Technologies (STEX), Hyperfine (HYPR), Edap Tms (EDAP), Apyx Medical (APYX), and Microbot Medical (MBOT). These companies are all part of the "medical equipment" industry.

How does Plus Therapeutics compare to Biosig Technologies?

Plus Therapeutics (NASDAQ:PSTV) and Biosig Technologies (NASDAQ:STEX) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 52.7% of Biosig Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Plus Therapeutics had 4 more articles in the media than Biosig Technologies. MarketBeat recorded 7 mentions for Plus Therapeutics and 3 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 0.46 beat Plus Therapeutics' score of -0.13 indicating that Biosig Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biosig Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Plus Therapeutics presently has a consensus target price of $58.00, indicating a potential upside of 894.85%. Biosig Technologies has a consensus target price of $9.00, indicating a potential upside of 656.30%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Plus Therapeutics is more favorable than Biosig Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Biosig Technologies has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Biosig Technologies has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Biosig Technologies	N/A	-717.92%	-336.75%

Plus Therapeutics has higher revenue and earnings than Biosig Technologies. Plus Therapeutics is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	7.70	-$22.39M	-$2.30	N/A
Biosig Technologies	$40K	5,388.92	-$462.77M	-$9.71	N/A

Summary

Plus Therapeutics beats Biosig Technologies on 9 of the 16 factors compared between the two stocks.

How does Plus Therapeutics compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Plus Therapeutics had 4 more articles in the media than Hyperfine. MarketBeat recorded 7 mentions for Plus Therapeutics and 3 mentions for Hyperfine. Hyperfine's average media sentiment score of 0.17 beat Plus Therapeutics' score of -0.13 indicating that Hyperfine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Plus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperfine has a net margin of -226.88% compared to Plus Therapeutics' net margin of -230.24%. Hyperfine's return on equity of -98.83% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Plus Therapeutics has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	12.12	-$35.57M	-$0.41	N/A
Plus Therapeutics	$5.21M	7.70	-$22.39M	-$2.30	N/A

Hyperfine has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Hyperfine currently has a consensus price target of $1.78, suggesting a potential upside of 26.48%. Plus Therapeutics has a consensus price target of $58.00, suggesting a potential upside of 894.85%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Hyperfine beats Plus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Plus Therapeutics compare to Edap Tms?

Plus Therapeutics (NASDAQ:PSTV) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Edap Tms has a net margin of -41.47% compared to Plus Therapeutics' net margin of -230.24%. Edap Tms' return on equity of -137.61% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Edap Tms	-41.47%	-137.61%	-40.62%

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 62.7% of Edap Tms shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 0.2% of Edap Tms shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Plus Therapeutics has higher earnings, but lower revenue than Edap Tms. Edap Tms is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	7.70	-$22.39M	-$2.30	N/A
Edap Tms	$70.53M	2.30	-$29.25M	-$0.81	N/A

Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Edap Tms has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market.

In the previous week, Plus Therapeutics had 3 more articles in the media than Edap Tms. MarketBeat recorded 7 mentions for Plus Therapeutics and 4 mentions for Edap Tms. Edap Tms' average media sentiment score of 0.63 beat Plus Therapeutics' score of -0.13 indicating that Edap Tms is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edap Tms	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Plus Therapeutics presently has a consensus target price of $58.00, suggesting a potential upside of 894.85%. Edap Tms has a consensus target price of $6.00, suggesting a potential upside of 38.89%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Plus Therapeutics is more favorable than Edap Tms.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Edap Tms	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Plus Therapeutics beats Edap Tms on 9 of the 16 factors compared between the two stocks.

How does Plus Therapeutics compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 15.2% of Apyx Medical shares are held by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Apyx Medical presently has a consensus price target of $6.50, suggesting a potential upside of 64.97%. Plus Therapeutics has a consensus price target of $58.00, suggesting a potential upside of 894.85%. Given Plus Therapeutics' higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Apyx Medical has higher revenue and earnings than Plus Therapeutics. Apyx Medical is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84M	3.12	-$11.21M	-$0.22	N/A
Plus Therapeutics	$5.21M	7.70	-$22.39M	-$2.30	N/A

In the previous week, Plus Therapeutics had 6 more articles in the media than Apyx Medical. MarketBeat recorded 7 mentions for Plus Therapeutics and 1 mentions for Apyx Medical. Apyx Medical's average media sentiment score of 0.00 beat Plus Therapeutics' score of -0.13 indicating that Apyx Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apyx Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Plus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apyx Medical has a net margin of -16.40% compared to Plus Therapeutics' net margin of -230.24%. Apyx Medical's return on equity of -88.47% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-16.40%	-88.47%	-14.94%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Apyx Medical has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Summary

Apyx Medical beats Plus Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Plus Therapeutics compare to Microbot Medical?

Microbot Medical (NASDAQ:MBOT) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Microbot Medical has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Microbot Medical's return on equity of -21.84% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Microbot Medical has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

In the previous week, Microbot Medical had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 10 mentions for Microbot Medical and 7 mentions for Plus Therapeutics. Microbot Medical's average media sentiment score of 0.74 beat Plus Therapeutics' score of -0.13 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Microbot Medical presently has a consensus target price of $7.50, indicating a potential upside of 333.53%. Plus Therapeutics has a consensus target price of $58.00, indicating a potential upside of 894.85%. Given Plus Therapeutics' higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Microbot Medical has higher earnings, but lower revenue than Plus Therapeutics. Microbot Medical is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A
Plus Therapeutics	$5.21M	7.70	-$22.39M	-$2.30	N/A

Summary

Microbot Medical beats Plus Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Plus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSTV vs. The Competition

Export

Metric	Plus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.20M	$2.99B	$6.25B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.32%
P/E Ratio	-2.53	17.04	20.79	25.05
Price / Sales	7.70	251.21	531.21	72.69
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	3.35	4.39	9.81	6.83
Net Income	-$22.39M	$74.99M	$3.55B	$335.69M
7 Day Performance	2.28%	-5.15%	-2.12%	-2.15%
1 Month Performance	-20.14%	-8.25%	-4.14%	-2.47%
1 Year Performance	-26.55%	26.23%	28.34%	27.13%

Plus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSTV Plus Therapeutics	2.4549 of 5 stars	$5.83 -0.2%	$58.00 +894.9%	-31.4%	$40.20M	$5.21M	N/A	20	Earnings Report Gap Up
STEX Biosig Technologies	2.0374 of 5 stars	$0.95 +2.5%	$9.00 +848.4%	N/A	$167.77M	$40K	N/A	50	News Coverage Earnings Report
HYPR Hyperfine	3.7911 of 5 stars	$1.75 +3.6%	$1.59 -9.3%	+125.4%	$165.55M	$11.40M	N/A	190
EDAP Edap Tms	3.9427 of 5 stars	$4.17 +1.0%	$6.00 +43.9%	+132.3%	$154.80M	$70.53M	N/A	230
APYX Apyx Medical	2.0144 of 5 stars	$3.92 +6.8%	$6.50 +65.8%	+164.4%	$153.68M	$52.84M	N/A	270

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSTV) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Plus Therapeutics (PSTV) Competitors

PSTV vs. STEX, HYPR, EDAP, APYX, and MBOT

How does Plus Therapeutics compare to Biosig Technologies?

Summary

How does Plus Therapeutics compare to Hyperfine?

Summary

How does Plus Therapeutics compare to Edap Tms?

Summary

How does Plus Therapeutics compare to Apyx Medical?

Summary

How does Plus Therapeutics compare to Microbot Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Plus Therapeutics (PSTV) Competitors

PSTV vs. STEX, HYPR, EDAP, APYX, and MBOT

How does Plus Therapeutics compare to Biosig Technologies?

Do institutionals & insiders have more ownership in PSTV or STEX?

Does the media favor PSTV or STEX?

Do analysts prefer PSTV or STEX?

Which has more volatility and risk, PSTV or STEX?

Is PSTV or STEX more profitable?

Which has higher earnings and valuation, PSTV or STEX?

Summary

How does Plus Therapeutics compare to Hyperfine?

Do insiders & institutionals hold more shares of HYPR or PSTV?

Does the media favor HYPR or PSTV?

Is HYPR or PSTV more profitable?

Which has better valuation and earnings, HYPR or PSTV?

Which has more volatility & risk, HYPR or PSTV?

Do analysts recommend HYPR or PSTV?

Summary

How does Plus Therapeutics compare to Edap Tms?

Is PSTV or EDAP more profitable?

Do institutionals and insiders hold more shares of PSTV or EDAP?

Which has preferable earnings and valuation, PSTV or EDAP?

Which has more volatility & risk, PSTV or EDAP?

Does the media favor PSTV or EDAP?

Do analysts rate PSTV or EDAP?

Summary

How does Plus Therapeutics compare to Apyx Medical?

Do insiders and institutionals hold more shares of APYX or PSTV?

Do analysts prefer APYX or PSTV?

Which has better earnings and valuation, APYX or PSTV?

Does the media refer more to APYX or PSTV?

Is APYX or PSTV more profitable?

Which has more risk & volatility, APYX or PSTV?

Summary

How does Plus Therapeutics compare to Microbot Medical?

Is MBOT or PSTV more profitable?

Do insiders & institutionals believe in MBOT or PSTV?

Which has more volatility and risk, MBOT or PSTV?

Does the media prefer MBOT or PSTV?

Do analysts rate MBOT or PSTV?

Which has preferable valuation & earnings, MBOT or PSTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools